INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.75, sa.7, 2021 (SCI-Expanded)
Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.